Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: david cohen who wrote (929)	11/26/1997 10:26:00 AM
From: dino	Respond to of 7041

In the conference call held by Joe P. last week. He kept saying the type of labeling Zonagen is approved for will be one of the larger issues and determine how competitive it can be or at least how it competes with Viagra. Can someone translate this for me and give an estimated probability of achieving the advantageous labeling.

To: david cohen who wrote (929)	11/26/1997 2:08:00 PM
From: Tokyo VD	Respond to of 7041

David, I respectfully ask that you tell us which analysts and urologists you spoke with to provide us with an understanding of the thoroughness of your work. I, for one, would like to state that your work seems like it took some time, so the information would be extremely important in helping others make an investment decision. Tokyo

To: david cohen who wrote (929)	11/27/1997 1:25:00 AM
From: Bruce Rosen	Read Replies (2) \| Respond to of 7041

Thanks David, for your thoughtful post. To answer your question, if you can stand short term volatility, I think this is an excellent time to begin building a position in Zonagen. It seems to me that the naysayers have gone all out to bring this company down and have only partially succeeded. I think the future news will be positive and any further attacks by Asensio or others will lack the shock value of the first. The company has achieved every milestone it has targeted; first, positive Phase III results; second, a tremendously successful secondary offering; third, the Schering deal. With each milestone reached, a bit of the long term risk is removed from the stock. The next major goal is timely FDA submission and ultimate approval. Your confidence after your due diligence mirrors my experience. Since this company will not be free of shorts until FDA approval occurs and maybe not even then, you should expect volatility and be careful useing margin for this stock. You might want to keep some funds in reserve to take advantage of any pullback. Hopefully, from my perspective, there won't be one and if not, you can always average up. One benefit of the vicious attack which Zonagen has weathered is that the stock is trading lower than it otherwise would, given the Schering deal. It seems that most medical professionals talk about this stock anonymously. This is more true of those negative on Zonagen. There have been some - David Ferguson, Harin Padma-Nathan and Irwin Goldstein among them, who have spoken publically and favorably of Zonagen's prospects. None that I know of have spoken for attribution in a negative way. If you can reveal your sources, please do. If not, your post was still an interesting and important one.